Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Nanopore Technologies Regulatory News (ONT)

Share Price Information for Oxford Nanopore Technologies (ONT)

Share Price is delayed by 15 minutes
Get Live Data
124.10    1.80 (1.47%)
Bid:
124.50
Ask:
125.10
Spread: 0.60 (0.482%)
Market Cap: £1.21b
ONT Live PriceLast checked at - London Stock Exchange

Intraday Oxford Nanopore Technologies Share Chart

ONT releases Remora:most comprehensive methylation

26 May 2022 07:00

RNS Number : 8443M
Oxford Nanopore Technologies plc
26 May 2022
 

Oxford Nanopore integrates "Remora": a tool to enable real-time, high-accuracy epigenetic insights with nanopore sequencing software MinKNOW

Oxford Nanopore has today released Remora, a high-performance tool for methylation analysis, into its operating software, MinKNOW, broadening access to direct, PCR-free nanopore sequencing that captures methylation across the whole genome.

From today, Oxford Nanopore users have easy access to precise whole genome methylation detection from PCR-free nanopore sequencing using Remora. By integrating Remora into MinKNOW the analysis of epigenetic modifications becomes seamless as it now runs in parallel to standard basecalling. This release complements the simplicity of native DNA sample preparation, which can be done in just 10 minutes using the same run, so at no additional cost. Nanopore sequencing is now the most comprehensive technology for characterising methylation, with the first releases aimed at targeting all CpG areas.

Native sequencing for greater epigenetic insight

Methylation detection has traditionally been dominated by using bisulphite treatment with short-read sequencing. Whilst this method has opened up the discovery of methylation sites, it also has limitations, increasing the cost and complexity of sequencing, owing to the requirement to repeat the run for essential comparison. Bisulphite cannot easily differentiate between methylation types such as 5mC/5hmC, or indeed add the detection of other modification types such as 6mA.

The Oxford Nanopore solution for detecting CpG methylation provides a number of advantages. No additional, complex sample preparation is required and epigenetic modification analysis can be performed across the whole genome during the experiment. Therefore, no additional toxic chemistry is needed, and the phasing of base modifications is put in genomic context with the ability to sequence long fragments of DNA. Nanopore technology enables base-modification analysis to be performed alongside nucleotide sequencing on a single read basis, so without the need to repeat the run.

Remora models demonstrate improved performance from a significantly simplified machine learning training process and they improve signal scaling which results in higher detection accuracy and quality filtered calls achieving 99.8% accuracy for 5mC in CpG contexts. This means that Remora delivers industry-leading methylation detection accuracy from a single read and provides biological insight into eukaryotic samples at only 20X coverage. Nanopore sequencing opens up the possibility of looking at methylation directly on individual DNA molecules, therefore representing how the DNA strands were in the cell, potentially the best and "most true" way of looking at DNA.

Marcus Stoiber, Senior Data Analyst, Oxford Nanopore commented:

"Detection of methylation from raw nanopore signal is an incredible strength of nanopore technology, but it has long been a cumbersome task to extract this information at the highest accuracy. Remora changes this and delivers epigenetic modifications at the same time as the highest accuracy canonical basecalls. As part of the team who developed Remora, we are delighted that it is now fully integrated and accessible to all Nanopore users and we're very excited see how the research community puts it to work in their groundbreaking research efforts."

Nanopore sequencing provides one platform for all your biology

These new tools will enable users to choose to sequence short fragments of DNA and perform methylation analysis of those fragments in real time for greater insights. DNA methylation is a process by which a methyl group is added to the DNA molecule, thereby modifying its behaviour but not altering the sequence. This modification of the DNA and its genetic expression is studied in epigenetics. The greater epigenetic insight that methylation analysis reveals is enabling discoveries across a breadth of genomic applications. Here are two examples from the Nanopore community; for further examples please visit the Resource Centre on at nanoporetech.com:

Ian Henderson, University of Cambridge, and his research group investigated Arabidopsis thaliana (a small flowering plant) centromeres and found a 'striking suppression of recombination around the centromere, as well as enrichment of epigenetic marks, like DNA methylation'. This was remarkable as it's only been since the advent of long-read sequencing that the centromeres can be studied in detail; previously, these regions have been too repetitive to sequence using short-read sequencing. Full presentation here.

Luna Djirackor, Oslo University Hospital, used nanopore analysis to show the future potential to classify brain tumours using methylation in as little as 91 minutes - quick enough for results to be returned to the operating table during brain surgery. Strikingly, in 60% of the samples sequenced in the study, the information obtained would have altered the pre-planned surgical strategy, demonstrating how this approach has the potential to significantly improve surgical outcomes in future. Full presentation here.

Remora can be accessed here and a dataset is available in EPI2ME labs for users to download here.

-end-

 

Further information from Marcus Stoiber, Senior Data Analyst, Oxford Nanopore Technologies: https://nanoporetech.com/resource-centre/video/ncm21/nanopore-methylation-better-way-mods

 

Direct DNA and RNA sequencing for methylation analysis with nanopore sequencing (animation): https://www.youtube.com/watch?v=7PraIiiN_Gc&list=PLxpxXZj-IgXyR0it4QjoBETC5JeEanW-o&index=17

About Oxford Nanopore Technologies

Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for real-time, high-performance, accessible and scalable analysis of DNA and RNA. The technology is used in more than 120 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses and whole environments.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAAAMLTMTATBJT
Date   Source Headline
30th Jun 20267:00 amRNSChanges to Director Roles and Responsibilities
12th Jun 20263:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
4th Jun 20262:30 pmRNSResult of AGM
1st Jun 20264:00 pmRNSIssue of Equity and Total Voting Rights
21st May 20267:01 amRNSLondon Calling Technology Update
21st May 20267:00 amRNSOxford Nanopore strengthens executive team
13th May 20263:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
12th May 20267:00 amRNSDirector/PDMR Shareholding
1st May 20263:00 pmRNSIssue of Equity and Total Voting Rights
1st May 20267:00 amRNSPublication of Annual Report and Notice of AGM
15th Apr 20265:30 pmRNSDirector/PDMR Shareholding - LTIP and DBP awards
14th Apr 20264:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
13th Apr 20263:00 pmRNSDirector/PDMR Shareholding - LTIP and DBP awards
1st Apr 20263:00 pmRNSIssue of Equity and Total Voting Rights
26th Mar 20263:00 pmRNSBlock Admission Application
4th Mar 20267:00 amRNS-RUpcoming Investor Events and Conferences
3rd Mar 20264:00 pmRNSGrant of LTIP awards; Director/PDMR Notification
3rd Mar 20267:00 amRNSDirector/PDMR Shareholding
2nd Mar 20264:00 pmRNSIssue of Equity and Total Voting Rights
2nd Mar 20267:00 amRNSAnnual results for the year ended 31 December 2025
27th Feb 20263:00 pmRNSUpdate on legal action against MGI Australia
27th Feb 20261:30 pmRNSDirector Declaration - John O'Higgins
12th Feb 20264:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
2nd Feb 20263:00 pmRNSIssue of Equity and Total Voting Rights
14th Jan 20264:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
12th Jan 20267:00 amRNSFull Year Trading Update and Notice of Results
7th Jan 20267:00 amRNS-RUpcoming Investor Events and Conferences
2nd Jan 20263:00 pmRNSIssue of Equity and Total Voting Rights
12th Dec 20253:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
8th Dec 20259:00 amRNSAGM Post-Meeting Shareholder Engagement Update
8th Dec 20257:00 amRNSAppointment of Francis Van Parys as CEO
1st Dec 20254:00 pmRNSIssue of Equity and Total Voting Rights
27th Nov 20257:00 amRNS-RUpcoming investor conferences
12th Nov 20254:30 pmRNSShare Incentive Plan - Director/PDMR Shareholding
7th Nov 20259:00 amRNSONT postpones investor event; reaffirms guidance
3rd Nov 20253:00 pmRNSIssue of Equity and Total Voting Rights
16th Oct 20257:00 amRNS-RUpcoming Investor Conferences and Events
14th Oct 20254:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
6th Oct 20255:30 pmRNSBlock listing Interim Review
1st Oct 20254:00 pmRNSIssue of Equity and Total Voting Rights
12th Sep 20254:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
2nd Sep 20257:00 amRNSInterim results for the 6 months ended 30 June 25
1st Sep 20255:00 pmRNSIssue of Equity and Total Voting Rights
13th Aug 20254:00 pmRNSShare Incentive Plan - Director/PDMR Notification
11th Aug 20257:00 amRNSChief Executive Officer Succession
8th Aug 20257:00 amRNSResult of Audit Tender
6th Aug 20257:00 amRNSCommencement of legal action against MGI Australia
1st Aug 20254:30 pmRNSIssue of Equity and Total Voting Rights
29th Jul 20257:00 amRNSHolding(s) in Company
21st Jul 20257:00 amRNSHalf Year Trading Update and Notice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.